Title: Retinal pigment epithelial cells reduce vascular leak and proliferation in

- retinal neovessels
- Short title: RPE cells reduce vascular leak in retinal neovessels
- Simone Tzaridis^{1,2}, Edith Aguilar², Michael I Dorrell^{1,3}, Martin Friedlander^{1,2}, Kevin T
- Eade^{1,2}
- ¹The Lowy Medical Research Institute, La Jolla, California, USA
- ² Department of Molecular Medicine, The Scripps Research Institute, La Jolla,
- California, USA
- ³Point Loma Nazarene University, San Diego, California, USA

20 Abstract

21 Retinal pigment epithelial (RPE)-cells possess numerous functions and may respond to 22 stress and damage of the neuroretina. In different neurodegenerative diseases, 23 including age-related macular degeneration (AMD), retinitis pigmentosa, and macular telangiectasia type 2 (MacTel), RPE-cells have been shown to proliferate and migrate 24 25 into the neuroretina, forming intraretinal pigment plaques. Though pigmentary changes 26 are associated with disease progression, it is not known if their presence is protective or 27 detrimental. In this study, we evaluated the impact of pigment plagues on vascular 28 changes and disease progression in patients with macular telangiectasia type 2 (MacTel), an example of a progressive neurodegenerative retinal disease. We then 29 studied underlying pathomechanisms using a mouse model mirroring these changes, 30 the very-low-density lipoprotein receptor mutant (VIdIr-/-) mouse. 31 32 In a retrospective, longitudinal study, we analyzed multimodal retinal images of patients 33 with MacTel and showed that pigment plagues were associated with a decrease in 34 vascular leakage and stabilized neovascular growth. Using genetic approaches, we analyzed changes in expression levels of relevant genes in the RPE and retinas of 35 VIdIr-/- mice during RPE-proliferation and migration. Our data indicated that RPE-cells 36 37 transitioned from an epithelial to a mesenchymal state ("epithelial-mesenchymal transition", EMT), proliferated and accumulated along neovessels. Using dextran 38 angiography and immunofluorescence, we demonstrated that the perivascular 39 40 accumulation of RPE-cells reduced vascular leakage. Pharmacologic inhibition of EMT led to a decrease in pigment coverage and exacerbation of neovascular growth and 41 exudation. 42

43	Our findings indicate that the proliferation, migration and perivascular accumulation of
44	RPE-cells may stabilize vascular proliferation and exudation, thereby exerting a
45	protective effect on the diseased retina. We conclude that interfering with this "natural
46	repair mechanism" may have detrimental effects on the course of the disease and
47	should thus be avoided.
48	
49	
50	
51	
52	
53	

55 Introduction

77

56 Retinal pigment epithelial (RPE)-cells possess numerous functions and may respond to 57 stress and damage of the neuroretina.[1] In different neurodegenerative diseases, 58 including age-related macular degeneration (AMD), retinitis pigmentosa, and macular telangiectasia type 2 (MacTel), RPE-cells have been proposed to proliferate and 59 60 migrate into the neuroretina, forming intraretinal pigment plaques. [2-5] Increasing 61 evidence suggests that during this process, RPE-cells transition from an epithelial to a mesenchymal state ("epithelial-mesenchymal transition", EMT), granting these cells 62 63 mesenchymal properties such as the ability to proliferate and migrate.[6, 7] Though pigmentary changes are commonly associated with disease progression, their role is 64 not fully understood. This association could represent a causative relationship whereby 65 the pigmentary changes contribute to disease progression, pigmentary changes could 66 be protective from worsening disease, or pigmentation could simply be an effect of other 67 68 disease-causing retinal changes that are unrelated to disease progression. 69 MacTel is an example of a progressive, neurodegenerative retinal disease that affects the central retina. Secondary vascular alterations are commonly observed.[8] Pigment 70 71 plaques are a frequent finding in MacTel and pigmented changes and vascular alterations have been found to collocate.[3, 5] Early vascular changes of the disease 72 include telangiectasia and increased vascular leakage, indicating a dysfunctional inner 73 blood-retina barrier.[8] With disease progression, a shift of vessels from the deep retinal 74 plexus to the outer retina as well as the formation of retinal-choroidal anastomoses and 75 76 outer retinal neovascularization has been described. These changes may precede the

formation of vision-threatening exudative subretinal neovascularization in some

cases,[9-12] and the origin of neovessels has been ascribed to the retinal rather than 78 the choroidal vasculature.[13-16] Recent imaging studies in MacTel proposed that the 79 formation of outer retinal neovascularization induced proliferation of the RPE, upon 80 contact between the RPE and outer retinal vessels.[17] It has been supposed that RPE 81 cells then use these abnormal vessels as a scaffolding to migrate into inner retinal 82 layers, where they form dense pigmented plagues.[5] Their role during disease 83 progression and their impact on vascular changes, including vascular leakage and 84 proliferation, have not yet been evaluated. We hypothesized that the perivascular 85 86 accumulation of RPE-cells may stabilize vascular proliferation and reduce vascular permeability. 87 The very-low-density lipoprotein receptor (VIdIr) mutant (VIdIr-/-) mouse represents a 88 common model of subretinal neovascularization, and is used to study disease 89 90 characteristics of MacTel, retinal angiomatous proliferation and other conditions.[18, 19] As in MacTel, in VIdlr-/- mice, neovascular changes originate from the retinal 91 vasculature. Retinal vessels proliferate, grow to the outer retina, and subsequently form 92 subretinal neovascularization. As the disease progresses, mice show a proliferation of 93 RPE cells with accumulation along neovascular tufts, followed by the migration of 94 pigmented cells along retinal vessels into the neuroretina.[18, 20, 21] These events 95

mirror the key neovascular and pigmentation-related events observed in MacTel and
other diseases with subretinal neovascularization, making the Vldlr-/- mouse an ideal
model to study these changes.

In this study, we aimed to (I) evaluate the role of pigment plaques on vascular changes
and disease progression in MacTel, and (II) study underlying disease mechanisms
using the Vldlr-/- mouse model mirroring these changes.

102 First, we show in a longitudinal, retrospective study of eyes with MacTel that perivascular pigment accumulation was associated with reduced vascular leakage and 103 104 decreased de novo formation of exudative neovascularization. We then explored whether the observed associations were causally related and which mechanisms led to 105 perivascular pigment accumulation in VIdlr-/- retinas. We found an enrichment of EMT-106 107 inducers and key mesenchymal markers in the RPE of VIdIr-/- mice. Pharmacologic inhibition of EMT-inducers led to decreased perivascular pigment accumulation and 108 109 enhanced neovascular growth and exudation in the VIdlr-/- model, indicating a 110 protective effect of pigmentary changes on vascular proliferation, mitigating vascular leak and proliferation. Based on our findings, we propose that EMT of the RPE, followed 111 by proliferation, migration and perivascular accumulation may function as a "natural 112 repair mechanism", exerting beneficial, anti-angiogenic and anti-exudative effects on the 113 diseased retina. As such, we conclude that interfering with these mechanisms may have 114 115 detrimental effects on the course of the disease and should thus be avoided.

116 **Results**

Perivascular accumulation of pigment is associated with decreased vascular leakage in eyes with MacTel. To investigate the impact of perivascular pigment accumulation on vessel leakage and proliferation in MacTel, we compared the longitudinal courses of eyes with and eyes without pigment plaque *de novo* formation. A total of 1216 eyes from 608 patients of 12 study centers were evaluated. 69 eyes from 69 patients (mean age 61.9 (range 53-71) years) were included and reviewed over a mean period of 41.6
months (range 24-60). 35 eyes (51%) showed a *de novo* development of pigmentary
changes, and 34 eyes did not. Pigment plaques predominantly accumulated along
vessels within the temporal parafovea (ETDRS subfield 5), usually sparing the fovea
(Additional figure 1). Rarely, an extension of changes to the superior, inferior, or nasal
parafovea (ETDRS subfields 2, 4, 3) was observed.

128 Longitudinal courses of eyes developing pigmented lesions differed from those without. A decrease in fluorescein leakage and stabilization of vessel proliferation was noted in 129 130 all but one eye with pigment plaques. The observed effects were, however, focal and limited to vessels covered with pigment. In these eyes, vessels lacking pigment plaques 131 showed stable, or rarely, increased leakage (observed in the nasal parafovea (ETDRS 132 subfield 3) of 4/35 eyes; see figure 1). Notably, coverage of vessels with pigment was 133 associated with a decrease in fluorescein leakage both in the early and late phase of 134 fundus fluorescein angiography (FFA), suggesting a sealing rather than a mere 135 shadowing effect associated with perivascular pigment accumulation. In eyes without 136 pigmentary changes, an increase in vascular leakage (in 16/34 eyes [47%]) or stable 137 138 leakage (in 18/34 eyes [53%]; table 1) was observed. Proliferation of vessels and increase in leakage were primarily observed within the temporal parafovea (ETDRS 139 subfield 5). Exemplary longitudinal courses are illustrated in figures 1 and 2. 140

Exudative subretinal neovascularization is considered a severe, vision-threatening complication of MacTel, and is associated with severe vascular leakage. The de novo formation of exudative subretinal neovascular membranes was less frequently observed in eyes with compared to eyes without pigment plaques (in 1/35 [3%] eyes vs 7/34

[21%]; Fisher's exact test, p=0.0275). Table 1 gives an overview of the clinical findings
in this study cohort.

147 In summary, patients with MacTel showed (I) an accumulation of pigment plagues along 148 abnormal retinal and subretinal vessels, (II) a decrease in vascular leakage that was associated with the development of pigment plaques, and (III) a decrease in exudative 149 150 subretinal neovascularization associated with the presence of pigment plaques. Based 151 on our findings in patients with MacTel, we hypothesized that (I) proliferating vessels may trigger the proliferation and perivascular accumulation of pigment. (II) Pigment 152 153 plaques may be formed by RPE cells that undergo EMT, proliferate, migrate and accumulate along proliferating vessels. (III) Perivascular pigment plagues may decrease 154 155 vascular leakage and stabilize vessel proliferation, thus having a beneficial effect on the 156 diseased retina.

To test these hypotheses, and to further evaluate disease mechanisms leading to perivascular pigment accumulation, we studied related changes in the Vldlr-/- mouse model. Similar to eyes with MacTel, the Vldlr-/- mouse model shows a proliferation of retinal vessels, formation of retinal-choroidal anastomoses and subretinal neovascularization. With disease progression, RPE-cells proliferate and accumulate along subretinal neovessels, and subsequently migrate along retinal vessels into the neuroretina.[18, 19, 21]

164 Proliferating retinal vessels trigger perivascular pigment accumulation.

We first set out to investigate whether vascular proliferation triggers the proliferation and perivascular accumulation of pigment. In the Vldlr-/- mouse model, retinal vessels begin

167	proliferating around P12, followed by the growth of retinal vessels to the outer retina,
168	and the formation of subretinal neovascular complexes around P16-P21.[22] RPE-cells
169	start proliferating around 4 weeks of age, accumulate along neovessels in the subretinal
170	space, and subsequently migrate along retinal vessels into the neuroretina.[19, 21, 23]
171	By inhibiting vascular proliferation using neutralizing antibodies against vascular
172	endothelial growth factor (VEGF), we found a reduction in neovascular tuft formation.
173	The ratio of pigmented to non-pigmented neovessels was, however, unchanged, and
174	pigment plaques only developed along proliferating neovessels (see Figure 3A),
175	suggesting that neovessels precede and are required for pigment plaque formation.
176	Pigment plaques are formed by RPE cells in VIdIr-/- retinas and express similar markers
177	as observed in eyes with MacTel
178	Previous findings in postmortem retinal samples of eyes with MacTel or retinitis
179	pigmentosa indicated that intraretinal pigment plaques originated from the RPE.[3]
180	Intraretinal lesions were found to express the epithelial cell marker cytokeratin-18 (CK-
181	18), that is specific to RPE-cells in the retina, but were negative for RPE65. Markers for
182	mesenchymal cells (alpha-smooth muscle actin [a-SMA]) and macrophages/ microglia
183	(IBA1) were also evaluated, but found to be absent.[3] To verify these findings in the
184	VIdIr-/- mouse model, we evaluated similar markers as previously described.[3]
185	Proliferating RPE cells within the subretinal space expressed CK-18 and RPE65. Some,
186	but not all of these cells also showed immunoreactivity for a-SMA (see Additional figure
187	2), indicating EMT of the RPE. Intraretinal pigment plaques, on the other hand,
188	expressed CK-18, but neither RPE65 nor IBA1 were detected (Additional figures 2 and
189	3). The expression of a-SMA was observed in single intraretinal pigmented lesions. The

latter were, however, overall smaller and less dense compared to lesions lacking a-SMA
expression, indicating a transitional, possibly less mature stage of these lesions
(Additional figure 2).

193 RPE-cells undergo EMT in VIdlr-/- retinas.

Under physiologic conditions, the RPE is formed by a monolayer of polarized cells. 194 195 Disintegration of the RPE monolayer and proliferation and migration of RPE-cells have been described in different degenerative retinal diseases, and have been attributed to 196 RPE cells transitioning from an epithelial to a mesenchymal state.[7] To test whether 197 198 RPE cells underwent EMT in the VIdlr-/- mouse model, we compared gene expression levels of known EMT-related genes in the RPE of VIdIr-/- mice and control VIdIr-/+ 199 littermates at P42. At this timepoint, RPE cells have been shown to proliferate and 200 accumulate along subretinal neovessels and start migrating along retinal vessels into 201 the neuroretina.[18, 19, 21] Using qPCR arrays, we found an enrichment of genes 202 coding for EMT pathways (SNAIL1/2) and different mesenchymal markers (vimentin, 203 fibronectin, N-cadherin) in the RPE of VIdIr-/- mice. Genes coding for epithelial markers 204 (beta-catenin, E-cadherin, zonula occludens-1 [ZO-1]), on the other hand, were 205 206 decreased (Figure 3B), indicating that RPE cells underwent EMT in this model. Next, we tested mRNA expression levels of known inducers of EMT in the retinas and 207 RPE of VIdlr-/- mice. The highest differences between VIdlr-/- and heterozygous control 208 209 littermates were found in fibroblast growth factor-2 (FGF2), which was increased 4-fold, 210 and in tumor-necrosis factor-alpha (TNFa), which was increased 2.5-fold. FGF2 is a known driver of EMT that, among other factors, has been described to play a role in 211 212 inducing EMT in RPE cells in proliferative vitreoretinopathy (PVR)[24]. FGF2 is also

213 known to play a role in inducing subretinal fibrosis, and has been shown to have proangiogenic properties. [25, 26] TNFa is a proinflammatory cytokine and a known inducer 214 of EMT in RPE cells.[7, 27] Elevated levels of TNFa have been detected in vitreous 215 216 samples and epiretinal membranes of patients with PVR[28].[27, 29] In vitro, TNFa has been shown to induce RPE cells to upregulate EMT markers and mesenchymal key 217 molecules.[30] Increased expression levels of TNF have previously been found in the 218 retinas of VIdlr-/- mice, and in particular at the level of the deep retinal plexus.[22] 219 Perivascular pigment decreases neovascular leakage and proliferation in VIdlr-/- retinas. 220 221 Similar to eyes with MacTel, we found that in the VIdlr-/- mouse model vessels covered 222 with pigment showed reduced dextran leakage compared to vessels not covered with pigment (Figure 3C). Perivascular pigment plaques expressed zonula occludens-1 (ZO-223 1), indicating the formation of tight junctions around proliferating vessels, thereby 224 possibly reducing vascular leakage (Figure 3D). Furthermore, on OCT, VldIr-/- mice 225 226 showed hyper-reflective changes at the level of the outer retina/ RPE that resemble 227 alterations observed in MacTel (Figure 3-E), which have been proposed to represent outer retinal neovascularization and proliferating RPE-cells.[17] Next, we set out to 228 229 investigate whether inhibiting EMT of the RPE may impact neovascular leakage and proliferation in the VIdIr-/- model. Mice treated with neutralizing antibodies against 230 FGF2 or TNFa from P21 to P42 showed a significant increase in vascular leakage and 231 in the size of neovascular complexes at P42 in comparison to IgG-treated control 232 animals (Figure 4A-C). Vascular leakage and perivascular pigment accumulation 233 234 showed a negative correlation in both treated and control animals (Figure 4D).

235 To test whether the observed morphological changes were associated with the inhibition of EMT, we compared gene expression levels of EMT-related genes in the RPE of 236 VIdIr-/- mice treated with FGF2, TNFa or control IgG. While no changes were observed 237 for EMT pathways, genes coding for epithelial markers were enriched, and 238 mesenchymal markers were decreased in animals treated with FGF2 or TNFa, 239 240 indicating the inhibition of EMT (Figure 4E). 241 In summary, we suggest that the perivascular accumulation of RPE-cells may stabilize neovascular proliferation and leakage, thereby exerting a beneficial, protective effect on 242 243 the diseased retina. Figure 5 summarizes the herein proposed mechanisms in a

schematic illustration.

245 **Discussion**

Pigment plaques can be found in different retinal diseases involving vascular pathology 246 247 and neurodegeneration. The origin of these changes has been attributed to RPE-cells, 248 accumulating along subretinal and retinal vessels, and migrating along vascular structures into the neuroretina.[3, 20] The role these changes may play during disease 249 progression is, however, not yet understood. In this study, we sought to evaluate the 250 impact of perivascular pigment plaques on the progression of vascular changes in eyes 251 252 with MacTel. We observed an association of perivascular pigment with a focal decrease in vessel permeability, and stabilization of vessel proliferation. The development of 253 254 exudative subretinal neovascular complexes was observed less frequently in eyes with compared to eyes without pigment plaque formation. In the literature, differing numbers 255 256 describing potential associations of pigment plaques with subretinal neovascularization 257 in MacTel have been reported. While Leung et al. found that in about 25% of

258 neovascular eyes, subretinal neovascularization coincided with or preceded pigmentary changes[5], Engelbrecht et al observed that pigmented lesions preceded the 259 development of neovascular membranes in all cases (in 11/11 eyes).[14] Meleth et al 260 261 reported the *de novo*-development of neovascularization in equal numbers of eyes with 262 and without preexistent pigmentations, respectively.[31] Differences between our data and previous reports may be explained by differing definitions of "neovascularization" 263 and "exudation", based on distinct imaging modalities, and differing in- and exclusion 264 265 criteria, resulting in study populations with varying disease stages, baseline 266 characteristics and observational periods. More recent studies evaluating longitudinal OCT-A data found that the formation of outer retinal neovascularization preceded 267 perivascular pigment accumulation in all cases.[32] Based on their findings on 268 269 multimodal retinal imaging, Mueller et al suggested that outer retinal neovascularization 270 induced proliferation of the RPE, once retinal vessels get in contact with the RPE[17], a 271 finding that is similar to previous observations in VIdIr-/- mice and other models.[18, 19, 272 21, 33 Our results are in line with these later findings of neovascularization preceding pigmentation and indicate that perivascular pigment accumulation is a focal process, 273 possibly triggered by vascular leakage and proliferation, and may represent a "repair 274 275 mechanism" of the disrupted RPE. Furthermore, our results may indicate that pigment plaques could be used as a biomarker to predict neovascular exudation and vascular 276 277 stabilization, respectively. Prospective, longitudinal studies are needed to verify our findings. 278

The reason why only a subset of MacTel patients develop pigment plaques currently
 remains obscure and warrants further studies. Limited observational periods and patient

numbers might have confounded our findings, representing potential limitations of thisstudy.

To study underlying disease mechanisms, we evaluated related pigmentary and 283 vascular changes in the VIdIr-/- mouse model. We showed that perivascular pigment 284 285 plaques expressed similar markers as previously described in postmortem retinal 286 specimens of eyes with MacTel and other diseases, verifying that these changes are formed by RPE-cells.[3, 20] We confirmed that pigment accumulation was associated 287 with a decrease in vessel leakage in the VIdIr-/- model. Our findings indicate that 288 perivascular pigment plaques may form tight junctions around proliferating vessels, as 289 290 indicated by ZO-1 localization, thereby reducing vascular leakage and stabilizing 291 neovascular growth. A similar effect of pigment plagues on vessel permeability has been previously reported by Jaissle et al, where migrating RPE-cells were observed to 292 293 form tight junctions with vascular endothelial cells, thus sealing retinal vessels in a 294 mouse model for retinitis pigmentosa.[33]

While dense pigment plagues within the neuroretina and subretinal space of VIdIr-/-295 mice showed a focal expression of ZO-1, genes coding for the same epithelial cell 296 297 marker were downregulated in the RPE of VIdIr-/- mice, indicating a broader loss of cell-298 cell contacts and epithelial cell state. This suggests a loss of adhesion in the general RPE monolayer, perhaps indicative of cells undergoing transition to a more migratory 299 phenotype. Taken together, these findings might indicate that RPE-cells undergo EMT, 300 proliferate and accumulate along subretinal and retinal vessels. Once migrating RPE-301 302 cells have found their new position, they may develop cell-cell contacts with neighboring 303 RPE-cells, forming dense plaques around the vessels, and possibly transition back to

304 an epithelial state ("mesenchymal-epithelial transition", MET). Similar mechanisms have been previously described to occur during cancer metastasis and organ 305 morphogenesis.[34, 35] The hypothesis that RPE cells undergo EMT, followed by MET, 306 307 in the VIdIr-/- model is further supported by the differences we found in the expression of epithelial and mesenchymal markers in VIdIr-/- mice compared to previous reports in 308 MacTel. In MacTel, intraretinal pigment plaques were found to only express the 309 epithelial marker CK18, while lacking any mesenchymal markers.[3] In the VIdIr-/-310 model, on the other hand, we observed that single intraretinal pigmented lesions also 311 312 expressed mesenchymal markers, possibly indicating the presence of different stages of lesions. This was particularly the case for lesions that were less dense, and thus 313 possibly less mature, indicating that some RPE-cells were still in a mesenchymal state, 314 315 before undergoing MET and forming dense, mature plagues around the vessels. In 316 MacTel, on the other hand, intraretinal pigment plaques usually develop within months and may form and progress over the course of several years, forming dense, organized 317 318 clusters of pigment around vessels. [3, 5] Thus, it is conceivable that lesions, once clinically detectable, are overall more mature, and RPE-cells within dense plaques no 319 320 longer possess mesenchymal properties, possibly having transitioned back to an epithelial state. Future studies are warranted to further explore the proposed 321 mechanisms. 322

EMT of RPE-cells has been described in different ocular conditions[7] and various inducers of EMT have previously been discussed.[7, 25, 29, 30] In the RPE of Vldlr-/mice, we found several known drivers of EMT to be enriched, with FGF2 and TNFa being the most significant ones in our model. While these factors could be related to

327 general neovascularization events in the VIdIr-/- retina, it is important to note that their inhibition actually reduced neovascularization and leakage, thus indicating a role in EMT 328 rather than general neovascularization. Other known drivers of EMT and/or fibrosis 329 330 have previously been identified in the VIdIr-/- model.[36, 37] Notably, EMT and TNFa/ NFkB pathways were previously found to be among the most significantly enriched 331 gene sets in RPE cells differentiated from induced pluripotent stem cells from MacTel 332 donors.[38] This underlines the clinical relevance and applicability of our findings in the 333 Vldlr-/- model. 334

Inhibiting EMT in the VldIr-/- model resulted in increased neovascular growth and
exudation, confirming the beneficial effect of perivascular pigment accumulation we had
clinically observed in patients with MacTel. Pigment plaques, on the other hand, have
been shown to be associated with a focal loss in retinal sensitivity ("absolute scotomas"
on fundus-controlled perimetry)[8, 39] and the pigment area with a decrease in visual
acuity in patients with MacTel[5], thus representing a mixed blessing.

341 Intravitreal VEGF inhibitors have been successfully used to treat numerous retinal

342 diseases showing vascular involvement. In MacTel, VEGF inhibitors have been

³⁴³ effectively applied in eyes showing subretinal neovascularization[40], while no functional

improvement has been reached in non-neovascular eyes.[41] The latter showed,

however, a (temporary) decrease in fluorescein leakage during treatment, followed by

an increase in leakage once treatment had been discontinued.[41] Notably, treated eyes

developed excessive pigmentation and fibrosis later on.[41, 42] In the Vldlr-/- model, we

348 found that perivascular pigment only developed when vascular proliferation was present

349 and pigment plaques only developed along proliferating vessels. Taken together, this

might further indicate that interfering with the herein proposed natural "repair

351 mechanism" of the diseased retina/RPE, by suppressing either EMT or vascular

leakage/ intraretinal proliferation, may have detrimental effects and thus should be

avoided in MacTel and related diseases.

354 **Conclusions**:

In summary, we showed that perivascular pigment accumulation is associated with a 355 356 decrease in vascular leakage and stabilization of neovascular growth in proliferative retinal diseases, such as MacTel, and respective animal models. We revealed 357 underlying mechanisms leading to perivascular pigment accumulation, and discussed 358 359 beneficial effects, changing our current understanding of these changes. Knowledge 360 about pathophysiological mechanisms is crucial for understanding the disease course and developing therapeutic interventions as well as choosing appropriate timepoints for 361 362 treatment. We conclude that interfering with this "natural repair mechanism" of the 363 diseased RPE may have detrimental effects on the course of the disease and should 364 thus be avoided.

365 Materials and Methods

Participants. In a retrospective, longitudinal approach, imaging data of affected
 participants from twelve participating sites of the multi-center Natural History Study of
 Macular Telangiectasia (MacTel Study) were evaluated. Protocol details of this study
 have been published previously.[43] The diagnosis of MacTel type 2 was based on
 characteristic morphologic findings on fundoscopy, OCT, fundus autofluorescence and
 fluorescein angiography[8], and was confirmed by the Moorfields Eye Hospital Reading

372 Centre, London, UK. Patients underwent annual study visits, and eves were reviewed over a minimum observational period of 24 months. The studies were approved by the 373 local ethics committees at each participating study site and were in adherence with the 374 375 Declaration of Helsinki. All participants provided informed consent. Data were collected at a minimum of two time points (at baseline and last available follow up visits), and 376 sites were selected based on the availability of longitudinal imaging data, including color 377 fundus photography (CFP), Spectral Domain-OCT (SD-OCT; volume scans of 15° x 10° 378 (high resolution mode, 97 scans) or 25° x 30° (high speed mode, 61 scans); Spectralis, 379 Heidelberg Engineering, Heidelberg, Germany), fundus autofluorescence (FA) and 380 fundus fluorescein angiography (FFA; 30°, centered on the fovea, images taken at 30 381 seconds, 1, 5 and 10 minutes after fluorescein injection). In a small subset of 382 participants, OCT-angiography (OCT-A) data were additionally available. 383 Inclusion criteria for this analysis were a confirmed diagnosis of MacTel, a full data set 384 including the examinations listed above and sufficient image quality. As pigmentary 385 changes have been shown to only develop in eyes showing disruptions of outer retinal 386 layers [44], and to ensure equal baseline conditions among both groups, only eyes with 387 388 intermediate disease stages were included. The latter was defined as visible disruption of the ellipsoid zone (EZ)/ photoreceptor layer on OCT, and disease stages 2-3 389 according to Gass and Blodi.[13] Eyes showing pigment plagues and/ or subretinal/ 390 391 sub-RPE neovascular membranes (stages 4 and 5 according to Gass and Blodi) at baseline were excluded. Further exclusion criteria were the presence of potentially 392 393 confounding retinal diseases including central serous chorioretinopathy, age-related

394 macular degeneration or diabetic retinopathy, and previous therapies including VEGF-

- inhibitors, vitreo-retinal surgery, photodynamic therapy or central laser treatment.
- Eyes were retrospectively divided into two groups, one group showing a *de novo*
- formation of pigment plaques at last follow up, and one group without any pigmentary
- ³⁹⁸ changes, and outcome parameters were compared between both groups.
- 399 Outcome parameters included changes in leakage on FFA (decreased, increased, or
- stable leakage within subfields 1-5 of the ETDRS grid) and a *de novo* development of
- 401 exudative subretinal neovascular membranes as observed on CFP, OCT, FFA, and
- 402 OCT-A (if available).

403 **Image grading and definitions.**

- 404 **Pigment plaques.** CFP and FA images were analyzed for the presence and position of
 405 pigment plaques at baseline and last follow up.
- Leakage on FFA. On FFA, vessels were graded for an (1) increase, (2) decrease, or
- 407 (3) no visible changes in fluorescein leakage at last follow up compared to baseline.
- Images were evaluated and compared at different time points (at 30 seconds, 1 minute,
- and 10 minutes after fluorescein injection) and within subfields 1-5 of the ETDRS grid.
- 410 **Neovascularization and exudation.** Previously described criteria were applied to
- 411 identify neovascular membranes on OCT, FFA, CFP, and OCT-A images (if
- 412 available).[16, 44] Neovascular exudation was defined as focal retinal thickening, sub-
- 413 or intraretinal fluid, and/or hemorrhages as observed on OCT and/ or CFP in
- 414 neovascular eyes.

415	Animals. All animal experimental procedures were approved by The Scripps Research
416	Institute Animal Care and Use Committee. Experiments were performed in accordance
417	with the NIH Guide for the Care and Use of Laboratory Animals (National Academies
418	Press, 2011). VldIr-/- mice (15) and control littermates (VldIr-/+ mice) (The Jackson
419	Laboratory) of up to 12 months of age were used for all animal experiments.
420	Intravitreal injections. All intravitreal injections were performed using a Hamilton
421	syringe and a 34-gauge needle (Hamilton), injecting $1\mu I$ of solutions containing
422	neutralizing antibodies against TNFa (250ng; MAB4101; R&D systems), FGF2 (200ng;
423	clone bFM-1; 05-117, Millipore Sigma) or VEGF164 (200ng; AF-493-NA; R&D systems).
424	For each of these antibodies, IgG isotype control antibodies were used as negative
425	controls (MAB005R, R&D systems; 12-371, Millipore Sigma; AB-108-C, R&D systems).
426	Intravitreal injections with antibodies against FGF2 or TNFa were performed at P21,
427	after subretinal neovascular tufts have formed, but before pigmented cells have started
428	proliferating or migrating[18, 45]. Retinas and RPE/choroid/sclera complexes were
429	analyzed for gene expression or immunofluorescence at P42. At this timepoint, RPE-
430	cells have been shown to proliferate and accumulate along subretinal neovessels and
431	have started migrating into the neuroretina, where they accumulate along retinal
432	vessels.[18, 19, 21, 45]
433	Intravitreal injections with antibodies against VEGF were performed at P12, when retinal
434	vessels have started proliferating and anti-VEGF treatment has been shown to be most

immunofluorescence imaging. At this timepoint, the normal RPE monolayer is disrupted,

effective in this model.[21, 36] Retinas were evaluated at P28 using

435

and clumps of RPE cells accumulate along neovascular tufts in the subretinal space of
Vldlr-/- mice.[19, 21]

Dextran angiography. For analyzing vascular leakage, Fluorescein isothiocyanate–
 dextran (FITC; 40,000 MW; Sigma-Aldrich) was perfused through the left ventricle of
 deeply anesthetized VIdIr-/- animals using 150µl of a 50mg/ml solution in PBS.

442 **Immunofluorescence**. Retinas and RPE/choroid complexes were dissected and

443 prepared for whole mounts or sectioning. For preparation of retinal cross-sections,

isolated eyes were fixed in 4% paraformaldehyde (PFA) for 4 hours, placed in 15%

sucrose overnight at 4°C, followed by 30% sucrose for 2 hours, and embedded in

446 Tissue-Tek OCT compound (Sakura Finetek) for subsequent cryosectioning. For

447 preparation of whole mounts, eyes were fixed in 4% PFA for one hour, and

retina/RPE/choroid complexes were dissected and laid flat. Whole-mount

retina/RPE/choroid complexes or cryosections were incubated in blocking buffer (10%

450 fetal bovine serum and 0.1% Triton X-100 in phosphate-buffered saline [PBS]) at 4°C

451 for 2 hours, followed by an incubation with primary antibodies in blocking buffer at 4°C

452 overnight. Specimens were then washed with PBS and incubated with Alexa Fluor-

453 conjugated secondary antibodies (Thermo Fisher) for 2 hours. Nuclei were stained

454 using DAPI (Vector Laboratories). Specimen were mounted in Vectashield Plus Antifade

455 Mounting Medium (Vectorlabs). Primary antibodies against ZO-1 (40-2200, Thermo

456 Fisher), RPE-65 (PA5-110315, Thermo Fisher), alpha-smooth muscle actin (ab124964,

457 Abcam), IBA1 (MA5-27726, Thermo Fisher) and Cytokeratin 18 (10830-1-AP,

458 Proteintech) were used. Endothelial cells were labeled using Fluorescent-conjugated

459 isolectin Griffonia Simplicifolia IB-4 (GS-Lectin) (I21412, Thermo Fisher). Images were

captured with a confocal laser scanning microscope (LSM 710, Zeiss) and processed
with the ZEN 2010 software (Zeiss). The NIH ImageJ software was used for quantifying
dextran-leakage (number of pixels positive for dextran), pigment accumulation (number
of pixels positive for pigment) and neovascular tufts (total numbers of visible tufts per
eye).

465 **Gene expression analyses.** For quantitative polymerase chain reaction (qPCR), 466 retinas and RPE/choroid complexes were isolated in 500µl Trizol. RNA isolation was performed using a RNeasy Plus Micro Kit (Qiagen) following the manufacturer's 467 468 instructions. 400ng RNA was used for real time-gPCR using the High-capacity cDNA Reverse transcriptase kit (Thermo Fisher). SYBR Green-based (Thermo Fisher) real-469 470 time quantitative PCR was performed on a QuantStudio 5 (Thermo Fisher) to analyze 471 mRNA expression levels of various gene products. Expression levels were normalized to Cyclophilin A. Sequences of primers used are listed in supplementary table 1. Data 472 were analyzed using the QuantStudio Design and Analysis Software 2.6.0 (Thermo 473 Fisher). 474

475 **Statistical analysis.** Statistical analyses were performed using GraphPad Prism,

version 10.1.0 (GraphPad Software, San Diego, CA, USA). Continuous variables were

477 described by using the mean ± standard deviation (SD), median and interquartile range

[IQR] and/ or ranges. Categorical variables were described in terms of frequency.

479 Unpaired t-test with Welch's correction was applied for comparing parameters between

two groups in normally distributed samples. Mann–Whitney test was used to compare

481 parameters between two groups in non-normally distributed samples. Kruskal-Wallis

test with Dunn's correction for multiple comparisons was used to compare data between

- 483 multiple groups. Fisher's exact test was applied to analyze contingency tables with
- 484 small sample sizes. Pearson correlation coefficient was calculated to determine linear
- 485 correlation between two parameters. Statistical tests applied for each experiment are
- detailed in the figure and table legends. A p-value <0.05 was accepted as statistically
- 487 significant.

488 **References**

- George SM, Lu F, Rao M, Leach LL, Gross JM: The retinal pigment epithelium: Development,
 injury responses, and regenerative potential in mammalian and non-mammalian systems. *Prog Retin Eye Res* 2021, 85:100969.
- 492 2. Li ZY, Possin DE, Milam AH: Histopathology of bone spicule pigmentation in retinitis pigmentosa.
 493 Ophthalmology 1995, 102(5):805-816.
- 4943.Yasvoina M, Yang Q, Woods SM, Heeren T, Comer GM, C AE, Fruttiger M: Intraretinal pigmented495cells in retinal degenerative disease. Br J Ophthalmol 2023, 107(11):1736-1743.
- 496 4. Miura M, Makita S, Sugiyama S, Hong YJ, Yasuno Y, Elsner AE, Tamiya S, Tsukahara R, Iwasaki T,
 497 Goto H: Evaluation of intraretinal migration of retinal pigment epithelial cells in age-related
 498 macular degeneration using polarimetric imaging. *Sci Rep* 2017, 7(1):3150.
- Leung I, Sallo FB, Bonelli R, Clemons TE, Pauleikhoff D, Chew EY, Bird AC, Peto T, MacTel Study G:
 Characteristics of Pigmented Lesions in Type 2 Idiopathic Macular Telangiectasia. *Retina* 2018,
 38 Suppl 1:S43-S50.
- 502 6. Tamiya S, Liu L, Kaplan HJ: Epithelial-mesenchymal transition and proliferation of retinal
 503 pigment epithelial cells initiated upon loss of cell-cell contact. *Invest Ophthalmol Vis Sci* 2010,
 504 51(5):2755-2763.
- 505 7. Zhou M, Geathers JS, Grillo SL, Weber SR, Wang W, Zhao Y, Sundstrom JM: Role of Epithelial506 Mesenchymal Transition in Retinal Pigment Epithelium Dysfunction. *Front Cell Dev Biol* 2020,
 507 8:501.
- 5088.Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HP: Macular509telangiectasia type 2. Prog Retin Eye Res 2013, 34:49-77.
- 5109.Tzaridis S, Heeren, Tjebo F.C., Mai, Clarissa, Thiele, Sarah, Holz, Frank G, Charbel Issa, Peter,511Herrmann, Philipp: Right-angled vessels in macular telangiectasia type 2. Br J Ophthalmol (in512press) 2019.
- 51310.Tzaridis S, Wintergerst MWM, Mai C, Heeren TFC, Holz FG, Charbel Issa P, Herrmann P:514Quantification of Retinal and Choriocapillaris Perfusion in Different Stages of Macular515Telangiectasia Type 2. Invest Ophthalmol Vis Sci 2019, 60(10):3556-3562.
- 51611.Breazzano MP, Yannuzzi LA, Spaide RF: Characterizing Retinal-Choroidal Anastomosis in Macular517Telangiectasia Type 2 with Optical Coherence Tomography Angiography. Retina 2020, 40(1):92-51898.
- 51912.Breazzano MP, Yannuzzi LA, Spaide RF: Genesis of Retinal-Choroidal Anastomosis in Macular520Telangiectasia Type 2: A Longitudinal Analysis. *Retina* 2020.
- 52113.Gass JD, Blodi BA: Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and522follow-up study. Ophthalmology 1993, 100(10):1536-1546.

523 14. Engelbrecht NE, Aaberg TM, Jr., Sung J, Lewis ML: Neovascular membranes associated with 524 idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 2002, 120(3):320-324. 525 15. Davidorf FH, Pressman MD, Chambers RB: Juxtafoveal telangiectasis-a name change? Retina 526 2004, 24(3):474-478. 527 Heeren TFC, Chew EY, Clemons T, Fruttiger M, Balaskas K, Schwartz R, Egan CA, Charbel Issa P, 16. 528 MacTel Study G: Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the 529 MacTel Area: MacTel Project Report Number 8. Ophthalmology 2020. 530 17. Mueller S, Gunnemann F, Rothaus K, Book M, Faatz H, Bird A, Pauleikhoff D: Incidence and 531 phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia type 532 2. Br J Ophthalmol 2021, 105(4):573-576. 533 18. Heckenlively JR, Hawes NL, Friedlander M, Nusinowitz S, Hurd R, Davisson M, Chang B: Mouse 534 model of subretinal neovascularization with choroidal anastomosis. Retina 2003, 23(4):518-522. 535 19. Hu W, Jiang A, Liang J, Meng H, Chang B, Gao H, Qiao X: Expression of VLDLR in the retina and 536 evolution of subretinal neovascularization in the knockout mouse model's retinal angiomatous 537 proliferation. Invest Ophthalmol Vis Sci 2008, 49(1):407-415. 538 20. Augustin M, Fialova S, Himmel T, Glosmann M, Lengheimer T, Harper DJ, Plasenzotti R, Pircher M, Hitzenberger CK, Baumann B: Multi-Functional OCT Enables Longitudinal Study of Retinal 539 540 Changes in a VLDLR Knockout Mouse Model. PLoS One 2016, 11(10):e0164419. 541 21. Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J, Banin E, Ramirez GA, Gasmi 542 M, Bird A et al: Antioxidant or neurotrophic factor treatment preserves function in a mouse 543 model of neovascularization-associated oxidative stress. J Clin Invest 2009, 119(3):611-623. 544 Sun Y, Lin Z, Liu CH, Gong Y, Liegl R, Fredrick TW, Meng SS, Burnim SB, Wang Z, Akula JD et al: 22. 545 Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos. J 546 Exp Med 2017, 214(6):1753-1767. 547 23. Li C, Huang Z, Kingsley R, Zhou X, Li F, Parke DW, II, Cao W: Biochemical Alterations in the 548 Retinas of Very Low-Density Lipoprotein Receptor Knockout Mice: An Animal Model of Retinal 549 Angiomatous Proliferation. Archives of Ophthalmology 2007, 125(6):795-803. 550 24. Chen HC, Zhu YT, Chen SY, Tseng SC: Wnt signaling induces epithelial-mesenchymal transition 551 with proliferation in ARPE-19 cells upon loss of contact inhibition. Lab Invest 2012, 92(5):676-552 687. 553 25. Matsuda Y, Nonaka Y, Futakawa S, Imai H, Akita K, Nishihata T, Fujiwara M, Ali Y, Bhisitkul RB, 554 Nakamura Y: Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 555 2 Aptamer in Animal Models of Retinal Disease. Mol Ther Nucleic Acids 2019, 17:819-828. 556 26. Schultz GS, Grant MB: Neovascular growth factors. Eye (Lond) 1991, 5 (Pt 2):170-180. 557 27. Wang CH, Cao GF, Jiang Q, Yao J: TNF-alpha promotes human retinal pigment epithelial (RPE) 558 cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of 559 Akt/mTORC1 signaling. Biochem Biophys Res Commun 2012, 425(1):33-38. 560 28. Ni Y, Qin Y, Huang Z, Liu F, Zhang S, Zhang Z: Distinct Serum and Vitreous Inflammation-Related 561 Factor Profiles in Patients with Proliferative Vitreoretinopathy. Adv Ther 2020, 37(5):2550-2559. 562 29. Limb GA, Alam A, Earley O, Green W, Chignell AH, Dumonde DC: Distribution of cytokine 563 proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res 1994, 564 13(11):791-798. 565 30. Boles NC, Fernandes M, Swigut T, Srinivasan R, Schiff L, Rada-Iglesias A, Wang Q, Saini JS, Kiehl T, 566 Stern JH et al: Epigenomic and Transcriptomic Changes During Human RPE EMT in a Stem Cell 567 Model of Epiretinal Membrane Pathogenesis and Prevention by Nicotinamide. Stem Cell Reports 568 2020, 14(4):631-647.

569	31.	Meleth AD, Toy BC, Nigam D, Agron E, Murphy RP, Chew EY, Wong WT: Prevalence and
570		progression of pigment clumping associated with idiopathic macular telangiectasia type 2.
571		Retina 2013, 33(4):762-770.
572	32.	Krivosic V, Lavia C, Aubineau A, Tadayoni R, Gaudric A: OCT of Outer Retinal Hyperreflectivity,
573		Neovascularization, and Pigment in Macular Telangiectasia Type 2. Ophthalmol Retina 2021,
574		5(6):562-570.
575	33.	Jaissle GB, May CA, van de Pavert SA, Wenzel A, Claes-May E, Giessl A, Szurman P, Wolfrum U,
576		Wijnholds J, Fischer MD et al: Bone spicule pigment formation in retinitis pigmentosa: insights
577		from a mouse model. <i>Graefes Arch Clin Exp Ophthalmol</i> 2010, 248(8):1063-1070.
578	34.	Pei D, Shu X, Gassama-Diagne A, Thiery JP: Mesenchymal-epithelial transition in development
579		and reprogramming. Nat Cell Biol 2019, 21(1):44-53.
580	35.	Yao D, Dai C, Peng S: Mechanism of the mesenchymal-epithelial transition and its relationship
581		with metastatic tumor formation. <i>Mol Cancer Res</i> 2011, 9(12):1608-1620.
582	36.	Usui-Ouchi A, Usui Y, Kurihara T, Aguilar E, Dorrell MI, Ideguchi Y, Sakimoto S, Bravo S,
583		Friedlander M: Retinal microglia are critical for subretinal neovascular formation. JCI Insight
584		2020, 5(12).
585	37.	Chen Q, Jiang N, Zhang Y, Ye S, Liang X, Wang X, Lin X, Zong R, Chen H, Liu Z: Fenofibrate Inhibits
586		Subretinal Fibrosis Through Suppressing TGF-beta-Smad2/3 signaling and Wnt signaling in
587		Neovascular Age-Related Macular Degeneration. Front Pharmacol 2020, 11:580884.
588	38.	Eade KT, Ansell BRE, Giles S, Fallon R, Harkins-Perry S, Nagasaki T, Tzaridis S, Wallace M, Mills EA,
589		Farashi S et al: iPSC-derived retinal pigmented epithelial cells from patients with macular
590		telangiectasia show decreased mitochondrial function. <i>J Clin Invest</i> 2023, 133(9).
591	39.	Tzaridis S, Friedlander M, Macular Telangiectasia Type 2-Phase CRG: Functional Relevance of
592		Hyper-Reflectivity in Macular Telangiectasia Type 2. Invest Ophthalmol Vis Sci 2021, 62(3):6.
593	40.	Barth T, Zeman F, Helbig H, Gamulescu MA: Intravitreal anti-VEGF treatment for subretinal
594		neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia. Int Ophthalmol
595		2018, 38(1):191-198.
596	41.	Charbel Issa P, Finger RP, Kruse K, Baumuller S, Scholl HP, Holz FG: Monthly ranibizumab for
597		nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol
598		2011, 151(5):876-886 e871.
599	42.	Kupitz EH, Heeren TF, Holz FG, Charbel Issa P: Poor Long-Term Outcome of Anti-Vascular
600		Endothelial Growth Factor Therapy in Nonproliferative Macular Telangiectasia Type 2. Retina
601		2015, 35(12):2619-2626.
602	43.	Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, Harrington MW, MacTel
603		Research G: Baseline characteristics of participants in the natural history study of macular
604		telangiectasia (MacTel) MacTel Project Report No. 2. Ophthalmic Epidemiol 2010, 17(1):66-73.
605	44.	Tzaridis S, Hess K, Heeren TFC, Bonelli R, Holz FG, Friedlander M: Hyper-reflectivity on optical
606		coherence tomography in macular telangiectasia type 2. <i>Reting</i> 2021.
607	45.	Li C. Huang Z. Kingslev R. Zhou X. Li F. Parke DW. 2nd. Cao W: Biochemical alterations in the
608		retinas of very low-density lipoprotein receptor knockout mice: an animal model of retinal
609		angiomatous proliferation. Arch Ophthalmol 2007. 125(6):795-803.
610		

612 Figures and legends

- Figure 1: Perivascular accumulation of pigment plaques decreases vascular leakage inpatients with MacTel.
- Longitudinal courses of three exemplary eyes showing a de novo formation of
- 616 perivascular pigment plaques, imaged with color fundus photography (CFP), blue-light
- autofluorescence (BAF), and fundus fluorescein angiography (FFA; early to
- 618 intermediate phase and late phase). A decrease in fluorescein leakage can be observed
- in vessels covered with pigment (yellow borderline), while vessels lacking pigment may
- show an increase in leakage and proliferation (blue borderline). The right column
- 621 illustrates enlarged BAF and FFA images of case #2 within the temporal and nasal
- 622 parafovea, respectively.
- 623
- Figure 2: Perivascular pigment accumulation stabilizes vessel growth and decreases
 neovascular exudation in eyes with MacTel.

626 Longitudinal courses of exemplary eyes with (cases 1-3) and without (cases 4-6) a de 627 novo development of pigment plagues. Perivascular pigment accumulation is associated with a decrease in fluorescein leakage on fundus fluorescein angiography 628 (FFA), and overall stable findings on spectral domain-optical coherence tomography 629 (SD-OCT). Note the increase in intraretinal hyper-reflectivity (black arrowheads) with 630 shadowing of underlying structures (white arrowheads) associated with pigment 631 632 accumulation. Eyes without pigmentary changes show an increase in fluorescein leakage that may be associated with the *de novo* development of exudative 633

neovascularization (white arrowheads). Hemorrhages may occur. CFP: color fundusphotography.

636

Figure 3: The Vldlr knockout mouse model mirrors vascular and pigmentary changes
 observed in MacTel.

A: Proliferating vessels trigger perivascular pigment accumulation in VIdlr-/- mice. 639 Neovascular (NV) tufts and perivascular pigment accumulation were analyzed using 640 641 GS-lectin staining and bright field images in P28 VIdIr-/- mice treated with intravitreal 642 injections of anti-VEGF (n=6) or control IgG (n=4) at P12. While anti-VEGF treatment 643 significantly decreased the total number of NV-tufts (Mann-Whitney test, *p=0.019), the 644 ratio of pigmented to non-pigmented NV-tufts was unchanged. Pigment plaques only developed along proliferating vessels. Error bars indicate the median and interguartile 645 646 range. B: Regulation of different genes coding for key molecules and inducers of 647 epithelial-mesenchymal transition (EMT) in the retina and RPE of VIdIr-/- mice at P42. Changes in genes between VIdIr-/- and VIdIr-/+ mice, as analyzed using a PCR array 648 for EMT, are shown. P values were calculated based on a Mann-Whitney test of the 649 650 replicate 2(-Delta Ct) values for each gene in the VldIr-/- and VldIr-/+ groups. *P < 0.05, **P < 0.01 (n=5 each). Median and IQR are shown for each gene. C: Dextran-651 652 angiography in a 12-months-old VIdlr-/- mouse depicts vessel and pigment proliferation and migration of pigmented cells along retinal vessels. Vessels covered with pigment 653 show reduced dextran leakage (enlarged images, yellow arrowheads) compared to 654 655 vessels not covered with pigment (white arrowheads). D: Pigment plagues cover 656 proliferating vessels (stained with GS-lectin) and express ZO-1, indicating the formation

657 of tight junctions along subretinal and retinal vessels in eves of 10-months-old VldIr-/mice. E: Vldlr knockout (vldlr-/-) mice show hyper-reflective changes at the level of the 658 outer retina (vellow arrowheads)/ retinal pigment epithelium (RPE: black arrowheads) 659 on optical coherence tomography that resemble alterations observed in MacTel. 660 Figure 4: Inhibition of epithelial-mesenchymal-transition (EMT) leads to enhanced 661 662 neovascular proliferation and leak in the VIdlr-/- model. A-C: Dextran angiography and GS lectin staining in flat mounted (A, upper panel) or 663 cryo-sectioned (A, middle and lower panel) Vldlr-/- mice treated with intravitreal 664 injections of neutralizing antibodies against TNFa (n=7) or FGF2 (n=7) at P21 showed a 665 significant increase in dextran leakage (A, upper panel; C), and a significant increase in 666 size of neovascular (NV) complexes (B) at P42 compared to IgG-treated controls (n=7). 667 Yellow-dotted boxes in A (upper panel) show enlarged neovascular complexes in 668 treated eyes. 669 670 GS-lectin staining and bright field images of cryo-sectioned VIdlr-/- (A, middle and lower panel) illustrate decreased pigment proliferation and perivascular accumulation in eyes 671 treated with anti-TNFa or anti-FGF2. D: Dextran-leakage (number of pixels positive for 672 dextran) was negatively correlated (Pearson r=-0.78; p<0.0001) with pigment 673

accumulation (number of pixels positive for pigment) in flat-mounted Vldlr-/- eyes. E and

F: Changes in genes coding for key molecules of EMT in VldIr–/– mice at P42 treated

with either anti-TNFa (E) or anti-FGF2 (F) compared to IgG-treated VIdIr-/- mice

- 677 (treatment at P21), as analyzed using a PCR array for EMT, are shown. While
- 678 mesenchymal key molecules (white bars) were downregulated, epithelial key molecules

679	were enriched (grey bars). P values were calculated based on a Mann-Whitney test of
680	the replicate 2(-Delta Ct) values for each gene. $*P < 0.05$, $**P < 0.01$ (n = 4 each).
681	Figure 5: Schematic illustration of the proposed interplay between RPE-cells and retinal
682	vessels in the VIdIr-/- model.
683	A: Proliferating vessels of the deep retinal plexus grow to the outer retina, form
684	neovascular tufts and get in contact with the RPE. RPE-cells transition from an epithelial
685	to a mesenchymal state, proliferate and migrate along retinal vessels into the
686	neuroretina, forming perivascular plaques.
687	B: Eyes treated with intravitreal antibodies against VEGF (anti-VEGF) show a reduction
688	in vessel proliferation and decreased numbers of neovascular tufts, while EMT of the
689	RPE is not impacted.
690	C: In eyes treated with intravitreal antibodies against TNFa or FGF2, epithelial-
691	mesenchymal transition (EMT) of the RPE is inhibited. RPE cells show reduced
692	proliferation, perivascular accumulation and migration. Neovascular tufts show more
693	leakage and increased lateral growth.
694	Created with BioRender.com
695	

Table 1: Clinical findings in the study cohort of patients with macular telangiectasia type2 (MacTel).

	Pigment plaques	No pigment plaques	Statistical significance
Eyes	35 [51%]	34 [49%]	ns*

Follow up period (months; mean [range])	41 [24-60]	39 [24-60]	ns*	
Fluorescein leakage temporal parafovea (ETDRS subfield 5)				
Increase	1 [3%]	16 [47%]	p<0.0001**	
Decrease	34 [97%]	0	NA	
Stable	0	18 [53%]	NA	
Exudative neovascularization	1 [3%]	7 [21%]	p=0.0275**	
Visual acuity: Loss of letters/year (mean [SD])	1.1 [2.3]	3.1 [3.9]	p=0.0125*	

698

⁶⁹⁹ *p-values were calculated based on an unpaired t-test with Welch's correction.

⁷⁰⁰ **p-values were calculated based on a Fisher's exact test.

701

703 Supplement:

- Supplementary Figure 1: Pigment accumulates along proliferating retinal vessels and
 retinal-choroidal anastomoses in eyes with MacTel.
- 706 Multimodal retinal images of four exemplary eyes with MacTel, including optical
- coherence tomography-angiography (enface scans of the following layers are shown:
- whole retina, superficial retinal plexus, deep retinal plexus and whole eye scans;
- vessels forming retinal-retinal and retinal-choroidal anastomoses are marked in red), B-
- scan Spectral domain (SD-) OCT, color fundus photographs (CFP), blue-light
- autofluorescence (BAF), and fundus fluorescein angiograms (FFA, late phase). Pigment
- plaques are indicated with arrow heads. On OCT, pigment plaques depict as hyper-
- reflective lesions. Horizontal lines on CFP images indicate the position of each B-scan.

714

- Supplementary Figure 2: Dense intraretinal pigment plaques express the retinal pigment
 epithelium marker Cytokeratin-18 (CK-18).
- 717 Immunofluorescence imaging of retinal sections of 11-months-old Vldlr-/- mice with GS-
- ⁷¹⁸ lectin (red) and CK-18, alpha-smooth muscle actin (a-SMA), IBA-1 or RPE65 (green).
- Nuclei are shown in blue (DAPI). Intraretinal pigment co-locates with CK-18, but not with
 a-SMA, IBA1 or RPE65.

- Supplementary Figure 3: RPE-cells form clusters around neovessels within the
- subretinal space, and express epithelial and mesenchymal markers.

- 724 Dense intraretinal pigment plaques (along vessels of the deep plexus) express the RPE
- marker Cytokeratin-18 (CK-18), but not RPE65. The expression of a-SMA was
- observed in single pigmented intraretinal lesions (black arrowhead). The latter
- appeared, however, overall less dense compared to those lesions lacking a-SMA
- expression (white arrowhead). Immunofluorescence imaging of flat mounted retinas of
- 12-months-old Vldlr-/- mice with GS-lectin (red) and CK-18, alpha-smooth muscle actin
- 730 (a-SMA), IBA-1 or RPE65 (green). Nuclei are shown in blue (DAPI).
- 731
- 732
- 733
- 734







anti-TNFa P42 (treatment at P21)

anti-FGF2 P42 (treatment at P21)



